Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{170500,
        author = {Mande Sandip Padmakar and Sourav Singh and Vansika and Nangare Mahesh Kailas and Rathod Nagnath Devidas and Aryan Niraj Kumar and Ashish shivajirao Tawar and Pranit Nagnath Budge},
        title = {A molecular docking study: Interaction of Favipiravir with 6VWW ( Nsp15 Endoribonulease) protein},
        journal = {International Journal of Innovative Research in Technology},
        year = {2024},
        volume = {11},
        number = {7},
        pages = {873-876},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=170500},
        abstract = {The goal of this work is to conduct molecular docking studies to investigate the interaction between the SARS-CoV-2 protein Nsp15 (PDB ID: 6VWW) and the antiviral drug Favipiravir. Nsp15 is an essential enzyme for the virus's replication, as it degrades viral RNA to evade the host immune response. Favipiravir, an antiviral agent, is known to inhibit viral RNA replication. In this study, docking simulations revealed that Favipiravir binds effectively to the active site of Nsp15, suggesting it could block the enzyme's function and disrupt viral RNA processing. These results highlight Favipiravir's potential as a therapeutic option for COVID-19, providing valuable insights for drug design and the development of antiviral treatments.},
        keywords = {Molecular docking, Favipiravir, antiviral agents, AutoDock, binding energy, drug design, computational chemistry.},
        month = {December},
        }